ERBB2 and breast carcinoma: Lastly, an unexpected implication for NRF2 emerged from a recent work wherein the combined use of an HER2 inhibitor, Trastuzumab with an EGFR-inhibitor, Nimotuzumab, was assessed in the context of HER2-overexpressing breast cancer.